|
Sign In to gain access to subscriptions and/or personal tools.
|
Candesartan prevents L-NAME-induced cardio-renal injury in spontaneously hypertensive rats beyond hypotensive effects
Daniel Casellas
Groupe Rein et Hypertension, Institut Universitaire de Recherche Clinique, Montpellier, France, casellas{at}iurc1.iurc.montp.inserm.fr
Abderraouf Herizi
Groupe Rein et Hypertension, Institut Universitaire de Recherche Clinique, Montpellier, France
Annie Artuso
Groupe Rein et Hypertension, Institut Universitaire de Recherche Clinique, Montpellier, France
Albert Mimran
Groupe Rein et Hypertension, Institut Universitaire de Recherche Clinique, Montpellier, France
Bernard Jover
Groupe Rein et Hypertension, Institut Universitaire de Recherche Clinique, Montpellier, France
Our goal was to assess the cardiovascular and renal protection afforded by angiotensin II type 1-receptor blockade against NG-nitro-L-arginine methyl ester (L-NAME)-exacerbated hypertension in young spontaneously hypertensive rats (SHR), in comparison with the antihypertensive drug, hydralazine. Male SHR were assigned to four groups (n=8 per group): no treatment (controls); L-NAME-treated group (20 mg/kg/day, 10 days, orally); co-treatment with L-NAME and hydralazine (15 mg/kg/day, by gavage); co-treatment with L-NAME and candesartan cilexetil (10 mg/kg/day, by gavage), i.e. at a dose that inhibited acute pressor responses to 5—20 ng angiotensin II. One animal died in the L-NAME group, and tail-cuff systolic blood pressure (SBP) increased significantly compared with controls to 201±5 mmHg. Albumin excretion increased 235-fold in L-NAME-treated rats. Heart weight index averaged 3.5±0.1 and 3.8±0.1 mg/g body weight (p<0.05) in control and L-NAME rats, respectively, indicating moderate cardiac hypertrophy induced by L-NAME. Preglomerular vascular lesions affected 63±6% of interlobular arteries and 10±2% of afferent arterioles (vs. 8±3 and 0.8±0.4% in controls, respectively). Hydralazine and candesartan cilexetil treatment similarly reduced SBP to 153±7, and 165±6 mmHg, respectively. However, candesartan provided more protection, in terms of no significant change in albuminuria (vs. 25-fold increase with hydralazine), regression of cardiac hypertrophy, frequency of vascular lesions and histological indices of renal injury maintained within control values. In conclusion, candesartan cilexetil prevented L-NAME-exacerbated hypertension and associated cardio-renal injury in young SHR, the beneficial effects exceeding those of hydralazine.
Key Words: cardiac hypertrophy • arterial remodelling • glomerular injury • interstitial fibrosis • vascular injury
References
- Zatz R., Baylis C. Chronic nitric oxide inhibition model six years on. Hypertens 1998;32:958-64.[Free Full Text]
- Kashiwagi M., Shinozaki M., Hirakata H. et al. Locally activated renin-angiotensin system associated with TGF-β1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J Am Soc Nephrol 2000;11:616-24.[Abstract/Free Full Text]
- Verhagen AM, Braam B., Boer P., Gröne H.-J, Koomans HA, Joles JA Losartan-sensitive renal damage caused by chronic NOS inhibition does not involve increased renal angiotensin II concentration. Kidney Int 1999;56:222-31.[Web of Science][Medline]
[Order article via Infotrieve]
- Pollock DM, Polakoski JS, Divish BJ, Opgenorth TJ Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition.Hypertens 1993;21:660-8.[Abstract/Free Full Text]
- Bouriquet N., Dupont M., Herizi A., Mimran A., Casellas D. Preglomerular sudanophilia in L-NAME hypertensive rats: involvement of endothelin. Hypertens 1996;27[part 1]:382-91.[Abstract/Free Full Text]
- Takase H., Moreau P., Küng CF, Nava E., Lüscher TF Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency. Effect of verapamil and trandolapril. Hypertens 1996;27:25-31.
- Michel J.-B, Xu Y., Blot S., Philippe M., Chatelier G. Improved survival in rats administered NG-nitro-L-arginine methyl ester due to converting-enzyme inhibition. J Cardiovasc Pharmacol 1996;28:142-8.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Casellas D., Benahmed S. Artuso A., Jover B. Candesartan and progression of preglomerular lesions in NG-nitro-L-arginine methyl ester hypertensive rats. J Am Soc Nephrol 1999;10:S230-S233.[Web of Science][Medline]
[Order article via Infotrieve]
- Numaguchi K., Egashira K.,Takemoto M. et al. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertens 1995;26[part 1]:957-62.[Abstract/Free Full Text]
- Takemoto M., Egashira K., Usui M. et al. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 1997;99:278-87.[Web of Science][Medline]
[Order article via Infotrieve]
- Bosse HM, Böhm R., Resch S., Bachmann S. Parallel regulation of constitutive NO synthase and renin at JGA of rat kidney under various stimuli. Am J Physiol 1995;269:F793-F805.[Web of Science][Medline]
[Order article via Infotrieve]
- Tomita H., Egashira K., Ohara Y. et al. Early induction of transforming growth factor-β via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertens 1998;32:273-9.[Abstract/Free Full Text]
- Ono H., Ono Y., Frohlich ED Nitric oxide synthase inhibition in spontaneously hypertensive rats. Systemic, renal and glomerular hemodynamics. Hypertens 1995;26:249-55.
- Komatsu K., Frohlich ED, Ono H., Ono Y., Numabe A., Willis GW Glomerular dynamics and morphology of aged spontaneously hypertensive rats: effects of angiotensin-converting enzyme inhibitor. Hypertens 1995;25:207-13.[Abstract/Free Full Text]
- Frohlich ED Influence of nitric oxide and angiotensin II on renal involvement in hypertension.Hypertens 1997;29[part 2]:188-93.[Abstract/Free Full Text]
- Casellas D., Bouriquet N., Artuso A. Nitric oxide and preglomerular vascular lesions in Lyon spontaneously hypertensive rats. Acta Physiol Scand 2000;168:133-8.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Ono H., Ono Y., Frohlich ED ACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats.Hypertens 1996;27:176-83.[Abstract/Free Full Text]
- Qiu C., Bruneval P., RoeckelA, Heudes D., Duong Van Huyen J.-P, Roux S. Mibefradil prevents L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats. J Hypertens 1999;17:1489-95.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Casellas D., Dupont M., Kaskel FJ, Inagami T., Moore LC Direct visualization of renin-cell distribution in preglomerular vascular trees dissected from rat kidney. Am J Physiol 1993;265:F151-F156.[Web of Science][Medline]
[Order article via Infotrieve]
- Casellas D., Bouriquet N., Herizi A. Bosentan prevents preglomerular alterations during angiotensin II hypertension. Hypertens 1997;30:1613-20.[Abstract/Free Full Text]
- Tharaux P-L., Chatziantoniou C., Casellas D., Fouassier L., Ardaillou R., Dussaule J-C. Vascular endothelin-1 expression and synthesis and effect on renal type 1 collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats. Circulation 1999;99:2185-91.[Abstract/Free Full Text]
- Li J-S., Deng LY, Grove K., Deschepper CF, Schiffrin EL Comparison of effect of endothelin antagonism and angiotensin-converting enzyme inhibition on blood pressure and vascular structure in spontaneously hypertensive rats treated with N
 -nitro-L arginine methyl ester. Correlation with topography of vascular endothelin-1 gene expression. Hypertens 1996;28:188-95. - Ono Y., Ono H., Frohlich ED Hydrochlorothiazide exacerbates nitric oxide blockade nephrosclerosis with glomerular hypertension in spontaneously hypertensive rats. J Hypertens 1996;14:823-8.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Ono Y., Ono H., Matsuoka H., Fujimori T., Frohlich ED Apoptosis, coronary arterial remodeling, and myocardial infarction after nitric oxide inhibition in SHR. Hypertens 1999;34:609-16.[Abstract/Free Full Text]
- Nakamura Y., Ono H., Frohlich ED Differential effects of T-and L-type calcium channel antagonists on glomerular dynamics in spontaneously hypertensive rats. Hypertens 1999;34:273-8.[Abstract/Free Full Text]
- Bidani AK, Griffin KA, Bakris G., Picken MM Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int 2000;57:651-61.
- Bouriquet N., Casellas D. Chronic L-NAME hypertension in rats and autoregulation of juxtamedullary preglomerular vessels. Am J Physiol 1995;269:F190-F197.[Web of Science][Medline]
[Order article via Infotrieve]
- Sventek P., Li J-S., Grove K., Deschepper CF, Schiffrin EL Vascular structure and expression of endothelin-1 gene in L-NAME-treated spontaneously hypertensive rats. J Hypertens 1996;27:49-55.
- Fujihara CK, Michellazzo SM, De Nucci G., Zatz R. Sodium excess aggravates hypertension and renal parenchymal injury in rats with chronic NO inhibition. Am J Physiol 1994;266:F697-F705.[Web of Science][Medline]
[Order article via Infotrieve]
- Barton M., d'Uscio LV, Shaw S., Meyer P., Moreau P., Lüscher TF ETA receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension 1998;31[part 2]:499-504.[Abstract/Free Full Text]
- Kassab S., Miller MT, Novak J., Reckelhoff, Clower B., Granger JP Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertens 1998; 31[part 2]:397-402.[Abstract/Free Full Text]
- Taal MW, Brenner BM Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int 2000;57:1803-17.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kashiwagi M., Shinozaki M., Hirakata H. et al. Locally activated renin-angiotensin system associated with TGF-β1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J Am Soc Nephrol 2000;11:616-24.[Abstract/Free Full Text]
- Muller DN, Mervaala EMA, Schmidt F. et al. Effect of bosentan on NF-kB, inflammation and tissue factor in angiotensin II-induced end-organ damage. Hypertens 2000;36:282-90.[Abstract/Free Full Text]
- Yanagitani Y., Rakugi H., Okamura A. et al. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertens 1999;33[part II]:335-9.[Abstract/Free Full Text]
Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 1 suppl,
S84-S90 (2001)
DOI: 10.1177/14703203010020011501
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Cordaillat, C. Rugale, D. Casellas, A. Mimran, and B. Jover
Cardiorenal abnormalities associated with high sodium intake: correction by spironolactone in rats
Am J Physiol Regulatory Integrative Comp Physiol,
October 1, 2005;
289(4):
R1137 - R1143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
